

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

## **ANNOUNCEMENT**

### **RESULTS ESTIMATE OF DONG-E-E-JIAO FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024**

On 9 October 2024, Dong-E-E-Jiao released its results estimate for the nine months ended 30 September 2024.

Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司) (“**Dong-E-E-Jiao**”) is a company incorporated in the People’s Republic of China. The shares of Dong-E-E-Jiao are listed on the Shenzhen Stock Exchange. As of the date of this announcement, Dong-E-E-Jiao is directly held as to 9.00% of its equity interests by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and approximately 23.50% is held by the Company through its non-wholly owned subsidiary, China Resources Dong-E-E-Jiao Company Limited (華潤東阿阿膠有限公司). The Group effectively controls approximately 22.31% of Dong-E-E-Jiao. Dong-E-E-Jiao is accounted for as a subsidiary of the Company.

On 9 October 2024, Dong-E-E-Jiao released its results estimate for the nine months ended 30 September 2024, in which, it announced that the net profit attributable to the shareholders of Dong-E-E-Jiao for the nine months ended 30 September 2024 is estimated to range from approximately RMB1,100.00 million to RMB1,175.00 million, representing an increase between approximately 40% and 50% as compared to that of approximately RMB783.6734 million for the same period last year, net profit excluding non-recurring gain or loss is estimated to range from approximately RMB1,014.95 million to RMB1,089.95 million, representing an increase between approximately 45% and 56% as compared to that of approximately RMB700.4239 million for the same period last year, and basic earnings per share is estimated to range from approximately RMB1.71 per share to approximately RMB1.83 per share (as compared to that of approximately RMB1.22 per share for the same period last year) (the “**Dong-E-E-Jiao Results Estimate**”).

The main reasons for the change in results are set forth as follows:

1. Dong-E-E-Jiao focuses on the annual development of “growth with quality”, taking the creation of Dong-E-E-Jiao’s distinctive new quality productivity as an important focus, implementing the principles of “reshaping values, businesses, organizations and ethos” and steadily and orderly advancing its various tasks. Adhering to a consumer-centric approach, Dong-E-E-Jiao combined integrated marketing and digital placement to continuously enhance brand power and strengthen brand penetration to promote consumer transformation; systematically constructed a “dual-wheel drive” growth model for pharmaceuticals and healthcare consumer products, and coordinated the promotion of the “One Centre and Three Highlands”, and actively expanded the synergistic development of the gel industry chain, putting Dong-E-E-Jiao onto a new track of sustainable high-quality development. Pipeline inventories of major products remained benign, the pricing system continued to be regulated, profitability was robust, investment returns were significantly enhanced, R&D investment was further increased, and the quality of operations was upgraded on all fronts.

2. In the future, Dong-E-E-Jiao will firmly assume the mission of inheriting and innovating the culture of Chinese medicine, adhere to the “1238” strategy as a guideline, further consolidate the position of the top-ranking brand of “Dong-E-E-Jiao, a national treasure of nourishment”, and comprehensively implement the “dual-wheel drive” strategy of Pharmaceuticals + Healthy Consumer Products. The “dual-wheel drive” business growth model has continued to consolidate the value leadership of the cornerstone business of pharmaceuticals on all fronts, and to build an innovative business development pattern for healthcare consumer products in a holistic manner. Through a comprehensive and scientific systematic layout, we will continue to strengthen and expand the main business of E-Jiao, actively expand the new tonic race, co-ordinate the cultivation of extended varieties, vigorously develop “E-Jiao+” and “+E-Jiao”, and comprehensively unleash the new kinetic power of new-quality productivity and strive to become the most trusted leader in nourishment and health for the public.

The Dong-E-E-Jiao Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. For the details of financial data, those to be disclosed in the quarterly report for the nine months ended 30 September 2024 to be issued by Dong-E-E-Jiao shall prevail.

The financial information in this announcement is limited to Dong-E-E-Jiao only and does not represent or provide a complete view of the operational or financial status of the Group.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board of Directors  
**China Resources Pharmaceutical Group Limited**  
**Bai Xiaosong**  
*Chairman*

PRC, 9 October 2024

*As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.*